Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

被引:197
作者
Baryakova, Tsvetelina H. [1 ]
Pogostin, Brett H. [1 ]
Langer, Robert [2 ]
McHugh, Kevin J. [1 ,3 ]
机构
[1] Rice Univ, Dept Bioengn, Houston, TX 77005 USA
[2] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA USA
[3] Rice Univ, Dept Chem, Houston, TX 77005 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
IONTOPHORETIC TRANSDERMAL SYSTEM; VACCINE SERIES COMPLETION; DISEASE-MODIFYING THERAPY; HUMAN GROWTH-HORMONE; QUALITY-OF-LIFE; MEDICATION ADHERENCE; DOSING FREQUENCY; ULCERATIVE-COLITIS; CARDIOVASCULAR-DISEASE; MULTIPLE-SCLEROSIS;
D O I
10.1038/s41573-023-00670-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Improving medication adherence is recognized as one of the most impactful and cost-effective strategies for improving the health of the general population. Here, Baryakova and colleagues assess the potential of next-generation drug delivery systems to mitigate many common impediments to adherence and discuss the impact that drug delivery systems have had across different disease types. Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past.
引用
收藏
页码:387 / 409
页数:23
相关论文
共 295 条
[81]   Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. [J].
Grant, Robert M. ;
Lama, Javier R. ;
Anderson, Peter L. ;
McMahan, Vanessa ;
Liu, Albert Y. ;
Vargas, Lorena ;
Goicochea, Pedro ;
Casapia, Martin ;
Guanira-Carranza, Juan Vicente ;
Ramirez-Cardich, Maria E. ;
Montoya-Herrera, Orlando ;
Fernandez, Telmo ;
Veloso, Valdilea G. ;
Buchbinder, Susan P. ;
Chariyalertsak, Suwat ;
Schechter, Mauro ;
Bekker, Linda-Gail ;
Mayer, Kenneth H. ;
Kallas, Esper Georges ;
Amico, K. Rivet ;
Mulligan, Kathleen ;
Bushman, Lane R. ;
Hance, Robert J. ;
Ganoza, Carmela ;
Defechereux, Patricia ;
Postle, Brian ;
Wang, Furong ;
McConnell, J. Jeff ;
Zheng, Jia-Hua ;
Lee, Jeanny ;
Rooney, James F. ;
Jaffe, Howard S. ;
Martinez, Ana I. ;
Burns, David N. ;
Glidden, David V. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (27) :2587-2599
[82]   Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach [J].
Greenberg, Rachel G. ;
Melloni, Chiara ;
Wu, Huali ;
Gonzalez, Daniel ;
Ku, Lawrence ;
Hill, Kevin D. ;
Hornik, Christoph P. ;
Cohen-Wolkowiez, Michael ;
Guptill, Jeffrey T. .
CLINICAL NEUROPHARMACOLOGY, 2016, 39 (05) :232-240
[83]  
GREENBERG RN, 1984, CLIN THER, V6, P592
[84]   Long-Term Nonclinical Pulmonary Safety Assessment of Afrezza, a Novel Insulin Inhalation Powder [J].
Greene, Stephanie F. ;
Nikula, Kristen J. ;
Poulin, Dominic ;
McInally, Kevin ;
Reynolds, Jack A. .
TOXICOLOGIC PATHOLOGY, 2021, 49 (02) :334-348
[85]   Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects [J].
Griffin, Paul ;
Elliott, Suzanne ;
Krauer, Kenia ;
Davies, Cristyn ;
Skinner, S. Rachel ;
Anderson, Christopher D. ;
Forster, Angus .
VACCINE, 2017, 35 (48) :6676-6684
[86]   A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression [J].
Gross, Robert ;
Yip, Benita ;
Lo Re, Vincent, III ;
Wood, Evan ;
Alexander, Christopher S. ;
Harrigan, P. Richard ;
Bangsberg, David R. ;
Montaner, Julio S. G. ;
Hogg, Robert S. .
JOURNAL OF INFECTIOUS DISEASES, 2006, 194 (08) :1108-1114
[87]   Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination [J].
Guarecuco, Rohiverth ;
Lul, Jennifer ;
McHugh, Kevin J. ;
Norman, James J. ;
Thapa, Lavanya S. ;
Lydon, Emily ;
Langer, Robert ;
Jaklenec, Ana .
VACCINE, 2018, 36 (22) :3161-3168
[88]  
Guest Julian F, 2005, Prim Care Respir J, V14, P88, DOI 10.1016/j.pcrj.2005.01.002
[89]   Strategy for Extending Half-life in Drug Design and Its Significance [J].
Gunaydin, Hakan ;
Altman, Michael D. ;
Ellis, J. Michael ;
Fuller, Peter ;
Johnson, Scott A. ;
Lahue, Brian ;
Lapointe, Blair .
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (06) :528-533
[90]   Non-adherence to heart failure medications predicts clinical outcomes: assessment in a single spot urine sample by liquid chromatography-tandem mass spectrometry (results of a prospective multicentre study) [J].
Gupta, Pankaj ;
Voors, Adriaan A. ;
Patel, Prashanth ;
Lane, Dan ;
Anker, Stefan D. ;
Cleland, John G. F. ;
Dickstein, Kenneth ;
Filippatos, Gerasimos ;
Lang, Chim C. ;
van Veldhuisen, Dirk J. ;
Metra, Marco ;
Zannad, Faiez ;
Samani, Nilesh J. ;
Jones, Don J. L. ;
Squire, Iain B. ;
Ng, Leong L. .
EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (07) :1182-1190